Evaluation of CD46 re-targeted adenoviral vectors for clinical ovarian cancer intraperitoneal therapy

Ovarian cancer accounts for >140 000 deaths globally each year. Typically, disease is asymptomatic until an advanced, incurable stage. Although response to cytotoxic chemotherapy is frequently observed, resistance to conventional platinum-based therapies develop rapidly. Improved treatments are t...

Descripción completa

Detalles Bibliográficos
Autores principales: Hulin-Curtis, S L, Uusi-Kerttula, H, Jones, R, Hanna, L, Chester, J D, Parker, A L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4947523/
https://www.ncbi.nlm.nih.gov/pubmed/27229159
http://dx.doi.org/10.1038/cgt.2016.22

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4947523/
https://www.ncbi.nlm.nih.gov/pubmed/27229159
http://dx.doi.org/10.1038/cgt.2016.22

Ejemplares similares